NLM Digital Collections

Search

Search Constraints

Start Over You searched for:

Search Results

121. A few states fell short in timely investigation of the most serious nursing home complaints: 2011-2015

123. Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices

124. Medicare payments for clinical diagnostic laboratory tests in 2016: year 3 of baseline data

125. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

126. Medicaid Fraud Control Units: investigation and prosecution of fraud and beneficiary abuse in Medicaid personal care services

127. Followup review: CMS's management of the quality payment program

128. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

129. Entities' experiences and perceptions of reporting the theft, loss, or release of select agents or toxins to CDC

130. Drug supply chain security: dispensers received most tracing information

132. Round two competitive bidding for oxygen: continued access for vast majority of beneficiaries

133. Round two competitive bidding for enteral nutrition: continued access for vast majority of beneficiaries

134. HRSA helped health centers with elevated risks and can continue to take additional steps

136. Part D plans generally include drugs commonly used by dual eligibles: 2018

138. Entities generally met Federal Select Agent Program internal inspection requirements, but CDC could do more to improve effectiveness

139. Opioid use in Medicare Part D remains concerning

140. CMS did not detect some inappropriate claims for durable medical equipment in nursing facilities